Background: Single nucleotide polymorphisms (SNPs) within the transcription factor 7-like 2 (TCF7L2) gene are well known risk variants for type 2 diabetes mellitus (T2DM). The association between TCF7L2 SNPs and T2DM has been investigated in several studies, but the results are controversial. In this study, we investigated whether the rs7903146, rs12255372, and rs290487 polymorphisms of TCF7L2 are associated with T2DM per se or metabolic traits related to this disease in a Kurdish ethnic group of Iran. Methods: In all, 173 patients with T2DM and 173 normoglycemic subjects were included in this study. All subjects were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genotypic and allelic frequencies were then analyzed in each group. Serum lipids, fasting glucose, fasting serum insulin, HOMA-IR, and HbA1c levels were determined by conventional methods. Results: T-allele and genotype frequencies of rs7903146, rs12255372, and rs290487 were significantly different between T2DM and control subjects 
INTRODUCTION
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by an elevated blood glucose level that is caused by defects in insulin secretion, insulin action, or both [1] . Today, 366 million people have diabetes worldwide, and the number is predicted to reach 552 million by 2030 [2] . Type 2 diabetes mellitus (T2DM) is the most common form of diabetes characterized by insulin resistance with a relative or real insulin deficiency [3] . Over the past 3 -4 decades, the global prevalence of T2DM has dramatically increased [1] . The exact cause for the current rise is not yet clearly known; however, genetic variations as well as environmental factors play a part in the development of T2DM [4] . Genetic susceptibility appears to have a crucial role in the etiology and manifestation of the disease [5, 6] . The TCF7L2 gene is located on chromosome 10q25.3 (114700201-114916063, NCBI build 36.2) [7] . Several SNPs of the TCF7L2 gene are well known risk variants for T2DM [8] ; however, the mechanism by which these variations predispose to T2DM is not exactly known. It has been suggested that TCF7L2 encodes a transcription factor that is expressed in the fetal pancreas and involved in the Wnt signaling pathway through regulating glucagon-like peptide (GLP-1), which, in addition to insulin, has a primary role in blood glucose homeostasis [9, 10] . The risk SNPs of TCF7L2 for T2DM include: rs7903146 (C/T), rs12255372 (G/T), and rs290487 (C/T). In recent years, the association between the SNPs of TCF7L2 mentioned and T2DM has been demonstrated in various ethnic groups [11] [12] [13] [14] [15] [16] [17] [18] , but the findings have been inconsistent in some populations [19] [20] [21] . To our knowledge, because the relationship between SNPs rs7903146, rs12255372, and rs290487 of TCF7L2 and T2DM in the Kurdish ethnic group of Iran have not been addressed yet and the controversial results from other populations, we aimed to explore the possible association between these TCF7L2 variants and T2DM and its metabolic quantitative traits in a sample of the Iranian Kurdish ethnic group. To these ends, we examined the allele and genotype frequencies of the above polymorphisms in T2DM and non-T2DM subjects, and detected their effects on anthropometric, diabetes, and obesity related parameters.
MATERIALS AND METHODS

Subjects and protocols
The protocol of this study was approved by the ethics committee of Ilam University of Medical Science, Iran (No: EC/92/H/131). The study population included 173 (males/females: 82/91; age: 54.97 ± 11.01 years) Iranian unrelated patients with type 2 diabetes and 173 (males/females: 73/100; age: 50.29 ± 9.64 years) Iranian unrelated healthy controls. All subjects originated from the Ilam and Kermanshah provinces situated in the west of Iran and belonged to the Kurdish ethnic group. Diabetic and healthy controls were distinguished based on their glycemic status, which was defined according to WHO 1997 criteria [22] . The control group only contained individuals with a normal fasting glucose level and negative family history of type 2 diabetes among first-degree relatives. The written informed consent was obtained from all participants before enrollment in the study. Screening included standardized questionnaires on personal data and clinical measurements such as age, gender, obesity, drug consumption during the past month, and medical or family history of diabetes [23] . All those who were not taking diabetes medication underwent a 2 hours oral glucose tolerance test (OGTT) after an overnight fast. Criteria for control selection were fasting glucose < 6.1 mmol/L and 2 hours plasma glucose < 7.8 mmol/L after OGTT. Diabetes was defined as fasting glucose ≥ 7.0 mmol/L, 2 hours glucose ≥ 11.1 mmol/L after OGTT, or use of hypoglycemic medication. Systolic and diastolic blood pressure was measured twice in the right arm of the subjects who had been resting for at least 10 minutes in a comfortable position. Signed informed consent was obtained from all subjects, and the study was approved by the Institutional Ethics Committee. All participants were interviewed to obtain clinical data and type 2 diabetes mellitus family histories. BMI was estimated through dividing weight in kilograms by the height in meters squared. Insulin resistance was assessed from glucose and insulin concentrations using the homeostasis model assessment of insulin resistance (HOMA-IR) equation [24] .
Sample preparation
Blood samples were collected from patients and controls in the morning, after an overnight (12 -14 hours) fasting. 5 mL of venous blood was withdrawn from the antecubital vein into Vacutainer tubes containing EDTA as the anticoagulant. To separate plasma, blood samples were centrifuged at 3000 rpm for 10 minutes. Supernatant was used for biochemical experiments, and the Buffy coat and red blood cell pellet were used for DNA extraction.
Biochemical assays
Serum blood glucose, triglycerides, total cholesterol, LDL-C and HDL-C levels were measured by the standard enzymatic method (Pars Azmon kit, Iran), using the auto analyzer system BT3000 (Biotechnica, Italy). Serum concentrations of insulin were assessed using an ELISA kit specific for human insulin according to the manufacturer's instructions (Monobind Inc., USA).
Genotyping
Leukocyte genomic DNA was extracted from the blood specimen using the standard procedure involving proteinase K and phenol/chloroform. The TCF7L2 rs7903146 polymorphic site (C/T) was amplified by the polymerase chain reaction (PCR) method using the primer pair 5´-TTAGAGAGCTAAG CACTTTTTAGGTA-3´ (forward) and 5´-GTTACTTG CCTTCCCTGTA ACTG-3´ (reverse). PCR was performed in a final volume of 25 µL containing 100 ng genomic DNA, 1.5 mmol/L MgCl2, 0.5 mmol/L of each dNTPs, and 0.5 pmol of each primer. After an initial denaturation of 2 minutes at 94°C, the samples were subjected to 30 cycles at 94°C for 1 minute, 55°C for 40 seconds, and 72°C for 30 seconds, with a final extension of 10 minutes at 72°C. The 102-bp product was di-gested with restriction enzyme RsaI for 8 hours at 37°C followed by agarose gel electrophoresis. The digested products were stained with ethidium bromide. T-allele was not cleaved by RsaI and gave a 102-bp band, and C-allele was cleaved into two bonds 77-and 25-bp. The fragment containing the rs12255372 polymorphic site (G/T) was amplified using the primer pair 5´-AGGAAT ATCCAGGCAAGCAT-3´ (forward) and a reverse primer of 5´-CTGGCACTCAGAAGAGAGTCAG-3´ (reverse). PCR conditions were the same as for rs7903146, except the annealing temperature was 61°C. The PCR product was electrophoresed on polyacrylamide gel and stained with ethidium bromide. The 99-bp product was digested with restriction enzyme NlaIII for 7 hours at 37°C followed by agarose gel electrophoresis. The digested products were stained with ethidium bromide. The T-allele was not cleaved by NlaIII and gave a 102-bp band, and the G-allele was cleaved into two bonds 78-and 21-bp. The TCF7L2 rs290487 polymorphic site (C/T) was amplified by the polymerase chain reaction (PCR) method using the primer pair 5´-AGGAGGCTGCCATATTGT TACTT-3´ (forward) and 5´-ACACCTTTCTCATTTT CAATTTCGC-3´ (reverse). PCR conditions were the same as for rs7903146, except the annealing temperature was 63°C. The PCR product was digested with the restriction enzyme AccII at 37°C for 7 hours followed by agarose gel electrophoresis. The C-allele was not cleaved by BtsI and gave a 153-bp band and the T-allele was cleaved into two bonds 128-and 25-bp.
Statistical analysis
All statistical analyses were carried out using the statistical program SPSS (version 19, SPSS, Chicago, IL, USA); Differences in genotype/allele frequencies were compared by the Chi-square test or Fisher's exact test where appropriate. One-way analysis of variance (ANOVA) was utilized to compare the clinical features among groups with different genotypes. Odds ratios (ORs) and 95% CI were calculated by logistic regression analysis using diabetes as a dependent variable and the genotypes as independent variables. We used the Pearson's goodness-of-fit chi-square (χ 2 ) test to evaluate the deviation from Hardy-Weinberg equilibrium. Armitage's trend test was applied to assess for the presence of association between different groups of genotypes. Other genetic models including dominant, recessive and multiplicative models were also considered to analyze SNP association [25] . Baseline quantitative results were expressed as mean ± standard deviation (SD) and compared with the Student's t test; the continuous variables that failed the normality test were logarithmically transformed before analysis. The variables transformed were triglyceride, insulin, and HOMA-IR. Statistical differences are based on analyses of log-transformed data, but means of untransformed data are presented in tables.
RESULTS
The clinical, anthropometrical, and biochemical characteristics of the participants are shown in Table 1 . Gender distribution was almost same in T2DM patients and their controls. The mean of age in T2DM patients and the control group was 54.98 ± 11.1 and 53.3 ± 9.7, respectively. All characteristics of the participants differed significantly between T2DM and normoglycemic control (p < 0.05). T2DM subjects had significantly higher values for BMI, triglyceride, HbA1c, glucose, total cholesterol, waist to hip ratio, LDL-C, HOMA-IR, diastolic and systolic blood pressure and insulin, and lower levels of HDL-C than normoglycemic control subjects (p < 0.05). The genotype distribution and relative allele frequencies of rs7903146 (C/T), rs12255372 (G/T), and rs290487 (C/T) polymorphisms at the TCF7L2 gene in the study subjects are showed in Table 2 . All three variants were in Hardy-Weinberg equilibrium in T2DM (χ 2 = 2.16, df = 1, p = 0.143 for rs7903146; χ 2 = 1.10, df = 1, p = 0.294 for rs12255372; χ 2 = 2.28, df = 1, p = 0.132 for rs290487) and control subjects (χ 2 = 0.423, df = 1, p = 0.52 for rs7903146CT; χ 2 = 1.058, df = 1, p = 0.304 for rs12255372GT ; χ 2 = 3.31, df = 1, p = 0.069 for rs290487). The corresponding risk associated with different genotypes of each SNP is shown in Table 2 . The distribution of the T-allele of rs7903146 was meaningfully (p = 0.000) higher in the T2DM subjects than in the control subjects (27% vs. 15%, respectively). The frequencies of genotypes CT and TT of this SNP also significantly differed between the study groups (p = 0.008 and 0.024, respectively). The CT genotype (OR = 1.98, 95% CI = 1.2 -3.28, p = 0.008), TT genotype (OR = 3.54, 95% CI = 1.18 -10.53, p = 0.024) and the dominant model (OR = 2.16, 95% CI = 1.34 -3.48, p = 0.002) of rs7903146 were associated with T2DM after adjustment for age, gender, and BMI. The frequency of the T-allele of rs12255372 variant was significantly (0.001) higher in the T2DM subjects compared with the control subjects (18% vs. 10%, respectively). Also, the distribution of genotypes GT and TT of this SNP were significantly higher in the T2DM subjects than in the control subjects (p = 0.005 and 0.046, respectively). After adjustment for age, gender, and BMI, the GT genotype (OR = 2.23, 95% CI = 1.28 -3.88, p = 0.005), TT genotype (OR = 4.25, 95% CI = 1.03 -17.61, p = 0.046), and the dominant model (OR = 2.2, 95% CI = 1.41 -4.08, p = 0.001 of rs12255372 gave a higher risk for T2DM. The T-allele of the rs290487 variant was significantly (0.002) different between study groups with the higher occurrence in the T2DM subjects than the control subjects (22% vs. 14%). The CT genotype of this SNP was more significantly frequent in T2DM subjects than the control subjects (p = 0.003). The carriers of the CT genotype of rs290487 variant showed a significantly increased risk for T2DM (OR = 2.24, 95%, CI = 1.32 - 
BMI -body mass index, WHR -waist to hip ratio, FPGfasting plasma glucose, HbA1c -hemoglobin A1c, TG -triglyceride, TC -total cholesterol, HDL-C -high-density lipoprotein cholesterol, LDL-C -low-density lipoprotein cholesterol, SBP -systolic blood pressure, DBP -diastolic blood pressure, FPI -fasting plasma insulin, HOMA-IR -homeostasis model assessment-insulin resistance.
3.82, p = 0.003). Similarly, the dominant model of this SNP was found to be significantly associated with T2DM (OR = 2.25, 95% CI = 1.36 -3.71, p = 0.002). We classified the clinical and biochemical characteristics of the study subjects according to the dominant model of rs7903146, rs12255372, and rs290487 (Table  3 , 4, and 5, respectively). Table 3 shows the characteristics of the study subjects categorized according to the dominant model for rs7903146. As shown in this table, T2DM subjects carrying the CT + TT genotypes of this variation had no significant difference in any variables as compared with those with the CC genotype. When comparing the clinical and biochemical features of control subjects with the T-allele and those without, it was found that subjects carrying the T-allele of rs7903146 had higher levels of total cholesterol (CC; 4.52 ± 1.03 vs. CT + TT; 5.00 ± 1.2 mmol/L, p = 0.009). Table 4 presents the clinical and biochemical characteristics of the study subjects categorized according to the dominant model of rs12255372. As shown in this table, normoglycemic subjects carrying the GT + TT genotypes of this variation had a significantly higher WHR (GG; 0.90 ± 0.059 vs. GT + TT; 0.93 ± 0.07, p = 0.038) as compared with those with the GG genotype. In T2DM subjects, no significant difference was found in any of the clinical or biochemical parameters between GG and GT + TT genotypes of rs12255372. As shown in Table 5 , among the T2DM and normoglycemic control subjects, there was no significant difference in any of the clinical or biochemical parameters between the CC and CT + TT genotypes of the rs290487.
DISCUSSION
One commonly used approach to define the genetic predisposition of T2DM is the candidate gene approach. This approach focuses on the search for an association between T2DM and sequence variants in or near biologically defined candidate genes which have been chosen based on their known physiological function. The importance of these variants or other nearby variants is tested by comparing the frequency in T2DM patients and normal glucose tolerant subjects [23, 26, 27] . Among all identified variants, the TCF7L2 genetic variants have the largest effect on the risk of type 2 diabetes [28] . However, the role of the TCF7L2 polymorphism in type 2 diabetes in the Kurdish ethnic group of Iran remains uncertain. The contribution of TCF7L2 variants to T2DM risk has been confirmed in some [11] [12] [13] [14] [15] [16] [17] [18] , but not all, populations studied so far [19] [20] [21] . In this study, we examined the association of rs7903146, rs12255372, and rs290487 in the TCF7L2 gene with T2DM and related metabolic traits using a case-control method. We selected these SNPs due to their previous association with T2DM [11] [12] [13] [14] [15] [16] [17] [18] . Based on our findings, there is an association between the T-allele and genotypes of 2.16 (1.34 -3.48 rs7903146, rs12255372, and rs290487 variants and T2DM. In a Japanese study, four SNPs of TCF7L2 (rs12255372, rs7903146, rs7901695, and rs11196205) were investigated and all four SNPs were found to be significantly associated with T2DM, with rs12255372 showing the strongest association [30] . An Indian study explored rs7903146, rs12255372, and rs4506565 of TCF7L2 and reported a significant association between all three SNPs and T2DM [29] . A study was conducted on Moroccans [31] and significant association between rs7903146 variant of TCF7L2 and T2D risk in this population was concluded. Furthermore, a positive association was also reported on Indian Asians [32, 33] , Pakistanis [34] , and Afro-Caribbeans. A study that was done in the Polish population showed that the TT genotype was associated with type 2 diabetes. The increased risk of type 2 diabetes was not observed for the CT genotype. A trend was found, but the results for the CT genotype were not significant [35] . The rs7903146 SNP of the TCF7L2 gene is associated with increased susceptibility to T2DM in the Chinese population [3] . Furthermore, research in a clinical trial that was conducted at 27 centers in the United States found that common variants in TCF7L2 (rs7903146 and rs12255372) seem to be associated with an increased risk of diabetes among persons with impaired glucose tolerance [39] . Recently, three independent studies in non-European populations including Chinese [14] , Pima Indians [37] , and Emirati Arabs [38] failed to find any association between TCF7L2 variants and T2DM. Also in a study that was conducted in the Arab population showed a weak or no association of T2DM with the two TCF7L2 variants (rs7903146 and rs12255372) [19] . Compared with CT + TT genotypes, the CC genotype of rs7903146 was significantly associated with the lower levels of total cholesterol in control subjects. To our knowledge, this has not been previously reported. In Tuscany, Italy, the TCF7L2 rs7903146 polymorphism was associated with lower insulin levels, smaller waist circumference, and lower risk lipid profiles in the general elderly population. Patients with diabetes who are carriers of the minor allele are less likely to have metabolic-syndrome features [36] . The reason for the apparent discrepancies between the studies, including ours, can be attributed to several factors such as the study design, sample size, population heterogeneity, and geneenvironment interactions [23, 27] . We also found that normoglycemic subjects carrying the GT + TT genotypes of the rs12255372 variation had a significantly higher WHR as compared with those with the GG genotype. This result is in accordance with the previously reported findings [40] . Based on our findings, among the T2DM and normoglycemic control subjects, there was no significant difference in any of the clinical or biochemical parameters between the CC and CT + TT genotypes of rs290487. To our knowledge, there is no published report for this association so far.
In conclusion, this is the first study performed in the Kurdish ethnic group from West Iran, in which a significance of genetic variations of the TCF7L2 gene was investigated in the pathogenesis of T2DM. The findings of our study revealed that rs7903146, rs12255372, and rs290487 polymorphisms of TCF7L2 are associated with the risk of T2DM.
